ScHARR-TAG has been allocated the following topic as part of the NICE Technology Appraisal Programme:
Adalimumab and infliximab (2nd line) for Crohn’s disease (moderate, active)
Interestingly, the draft scope includes biosimilars within the appraisal – the European Commission has recently approved the first infliximab biosimilars. How the evidence on these products will be factored in should be interesting…….